南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 2024 年度持续督导跟踪报告 2022 年 8 月 11 日，南京麦澜德医疗科技股份有限公司（以下简称"麦澜德" 或"公司"）在上海证券交易所科创板上市。根据《证券发行上市保荐业务管理 办法》《上海证券交易所科创板股票上市规则》等相关规定，南京证券股份有限 公司（以下简称"南京证券"或"保荐机构"）作为麦澜德的保荐机构，对麦澜 德进行持续督导，持续督导期为 2022 年 8 月 11 日至 2025 年 12 月 31 日。 2024 年度，南京证券对麦澜德的持续督导工作情况如下： | 序号 | 工作内容 | 持续督导情况 | 保荐机构已建立并有效执行了持 | | | | --- | --- | --- | --- | --- | --- | | 建立健全并有效执行持续督导工作制度，并针对 | 续督导制度，并制定了相应的工 | 1 | 具体的持续督导工作制定相应的工作计划 | | | | 作计划 | 根据中国证监会相关规定，在持续督导工作开始 | 保荐机构已与麦澜德签订保荐协 | | | | | 前，与上市公司或相关当事人签署持续督导协 | 议，该协 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of 麦澜德 in the medical device industry, showcasing its recent achievements and financial metrics [1][2] - 麦澜德's stock closed at 29.62 yuan, with a rolling PE ratio of 28.17, marking a new low in 32 days, and a total market capitalization of 29.62 billion yuan [1] - The company ranks 62nd in the medical device industry, which has an average PE ratio of 49.20 and a median of 36.56 [1][2] Group 2 - For Q1 2025, 麦澜德 reported revenue of 1.18 billion yuan, reflecting a year-on-year increase of 13.36%, and a net profit of 3985.97 million yuan, up by 9.85%, with a gross margin of 70.85% [2] - The company specializes in the research, production, sales, and services of products related to pelvic floor and obstetric rehabilitation, focusing on women's health [1] - 麦澜德 has been recognized as a "national manufacturing single champion" and is the first national-level specialized and innovative "little giant" enterprise in its field, indicating strong market competitiveness and innovation capabilities [1]

南京麦澜德医疗科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688273 证券简称：麦澜德 南京麦澜德医疗科技股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 | | | 南京麦澜德医疗科技股份有限公司 2024 年年度股东大会会议资料 南京麦澜德医疗科技股份有限公司 2024 年年度股东大会会议须知 为维护全体股东的合法权益，确保南京麦澜德医疗科技股份有限公司（以下 简称"公司"）股东大会顺利进行，根据《中华人民共和国证券法》《中华人民 共和国公司法》等法律法规及《南京麦澜德医疗科技股份有限公司章程》和公司 《股东大会议事规则》的相关规定，制定以下会议须知，请出席股东大会的全体 人员严格遵守。 一、全体参会人员应以维护全体股东的合法权益、保障会议的正常秩序和议 事效率为原则，自觉履行法定义务。 二、为保证股东大会的严肃性和正常秩序，除出席会议的股东（含股东代理 人，下同）、董事、监事、高级管理人员、公司聘请的律师及公司董事会要求的 人员以外，公司有权依法拒绝其他人士入场。为确认出席股东大会的股东或其他 出席者的出席资格，会议工作人员将对出席会议者的身份进行必要的核对工作， ...

| | 信 | | | | | | --- | --- | --- | --- | --- | --- | | 002819 | 东方中 | 5.46 | 5.04 | 2484.46 | 7.62 | | | 科 | | | | | | 603610 | 麒盛科 | 10.03 | 2.24 | 1914.18 | 22.31 | | | 技 | | | | | | 002173 | 创新医 | 5.13 | 11.12 | 784.62 | 1.77 | | | 疗 | | | | | | 688273 | 麦澜德 | 2.78 | 6.54 | 319.50 | 4.55 | | 300793 | 佳禾智 | 3.28 | 4.14 | 232.19 | 0.95 | | | 能 | | | | | | 002925 | 盈趣科 技 | 6.67 | 1.43 | 154.79 | 0.91 | | 601718 | 际华集 团 | 1.55 | 0.61 | 105.50 | 1.50 | | 300678 | 中科信 | 3.62 | 2.35 | 93.97 | 0.46 | | | 息 | | ...

证券代码：688273 证券简称：麦澜德 公告编号：2025-016 南京麦澜德医疗科技股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 案之日起 12 个月内。具体内容详见公司于 2024 年 7 月 2 日在上海证券交易所网 站（www.sse.com.cn）披露的《关于以集中竞价交易方式回购股份的回购报告书》 （公告编号：2024-041）。 公司 2024 年半年度权益分派实施后，公司以集中竞价交易方式回购股份价格 上限由不超过人民币 32.00 元/股（含）调整为不超过人民币 31.61 元/股（含）。具 体内容详见公司于 2024 年 10 月 12 日在上海证券交易所网站（www.sse.com.cn） 披露的《关于 2024 年半年度权益分派实施后调整回购价格上限的公告》（公告编 号：2024-061）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司应在每个月 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and business performance [1][2]. Core Insights - The company achieved a revenue of 425 million yuan in 2024, representing a year-over-year increase of 24.57%, with a net profit of 102 million yuan, up 13.10% year-over-year [1][2]. - The reproductive rehabilitation segment showed exceptional growth, with revenue reaching 110 million yuan in 2024, a significant increase of 126.56% year-over-year, driven by product upgrades and market expansion [2]. - The company is focusing on new product promotions, which may temporarily pressure gross margins, but the diverse product pipeline is expected to drive future growth [2]. Financial Summary - Total revenue for 2024 was 425 million yuan, with a projected growth rate of 17.0% for 2025, reaching 497 million yuan [3]. - The gross margin for the main business in 2024 was 72.25%, a decrease of 2.40 percentage points year-over-year [2]. - The company forecasts net profits of 136 million yuan in 2025, reflecting a year-over-year growth of 33.4% [3]. Business Performance - The company has strengthened its competitive position in the pelvic rehabilitation field, achieving revenue of 167 million yuan in this segment, a year-over-year increase of 3.02% [2]. - The sports rehabilitation segment saw a revenue increase of 40.76%, reaching 18.06 million yuan in 2024, supported by the sales growth of magnetic series products [2]. - The company is investing in R&D to develop innovative products, including a new generation of ultrasound diagnostic systems and radar magnetic stimulators, which are expected to enhance its market position [2].

Investment Rating - The report assigns a "Buy" rating for the company 麦澜德 (688273) based on its strong performance and growth potential [1]. Core Views - The company achieved a revenue of 425 million yuan in 2024, representing a year-over-year growth of 24.57%, with a net profit of 102 million yuan, up 13.10% year-over-year [1][2]. - The reproductive rehabilitation segment showed exceptional growth, with revenue reaching 110 million yuan in 2024, a significant increase of 126.56% year-over-year, driven by product upgrades and market expansion [2]. - The company is focusing on new product promotion, which has temporarily pressured gross margins, but a strong pipeline of innovative products is expected to drive future growth [2]. Financial Summary - The company’s total revenue is projected to grow from 497 million yuan in 2025 to 693 million yuan in 2027, with year-over-year growth rates of 17.0%, 17.7%, and 18.5% respectively [3]. - The net profit attributable to the parent company is expected to increase from 136 million yuan in 2025 to 201 million yuan in 2027, with growth rates of 33.4%, 22.0%, and 21.4% [3]. - The gross margin for the main business in 2024 was 72.25%, slightly down by 2.40 percentage points year-over-year, primarily due to new product promotions [2][3].

Investment Rating - The investment rating for the company is "Buy" (maintained) due to rapid growth in consumables business and proactive layout in potential sectors [5][6]. Core Views - The company is expected to achieve revenues of 5.29 billion, 6.70 billion, and 8.48 billion RMB for the years 2025, 2026, and 2027 respectively, with year-on-year growth rates of 24.51%, 26.67%, and 26.66% [6][7]. - The net profit attributable to the parent company is projected to be 1.30 billion, 1.69 billion, and 2.20 billion RMB for the same years, with growth rates of 28.31%, 29.70%, and 30.32% [6][7]. - The company maintains a leading position in the pelvic rehabilitation field and has diversified its rehabilitation product lines, supporting the "Buy" rating [6]. Financial Performance Summary - In 2024, the company achieved a revenue of 4.25 billion RMB (yoy +24.57%) and a net profit of 1.02 billion RMB (yoy +13.10%) [8]. - For Q1 2025, the company reported a revenue of 1.18 billion RMB (yoy +13.36%) and a net profit of 0.40 billion RMB (yoy +9.85%) [8]. - The company's consumables and accessories revenue reached 1.19 billion RMB in 2024, showing a year-on-year increase of 26.21% [8]. Profitability and Margins - The gross margin for the medical device business in 2024 is 74.47%, with the main business gross margin at 72.25% [8]. - The net profit margin is reported at 25.65%, reflecting a decrease due to lower gross margins and increased operating expenses [8]. Future Outlook - The company is actively exploring potential applications in cutting-edge fields such as brain-machine interfaces and AI skin health assessment, indicating a strategic focus on innovation and growth [8].

证券代码：688273 证券简称：麦澜德 公告编号：2025-015 南京麦澜德医疗科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 召开日期时间：2025 年 5 月 14 日 14 点 00 分 召开地点：南京市雨花台区凤展路 32 号 A2 栋北 公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 14 日 至2025 年 5 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 股东大会召开日期：2025年5月14日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股 ...